Necrotizing enterocolitis (NEC) is described in the packet definition as a devastating disease affecting mostly the intestine of premature infants. The definition states that bacteria invade the intestinal wall, causing local infection and inflammation that can destroy the bowel wall. The packet lists the synonym NEC and a perinatal subtype, and includes Orphanet and GARD identifiers. It has no GeneReviews chapter, no onset category, and no certified phenotype records.

The packet contains no structured phenotype records, characteristic findings, or onset information, so symptom frequencies and presentation details are unknown in this packet. The definition describes the disease course only in terms of bowel wall destruction, intestinal perforation with spillage of stool into the abdomen, and overwhelming infection that can result in death.

The structured gene field and inheritance field are empty in this packet, so no genes or inheritance pattern are named; this reflects the packet and is not a statement that none exist. The definition describes a process in which bacteria invade the intestinal wall and cause infection and inflammation that can destroy the bowel wall.

The packet contains no diagnostic methods field and no GeneReviews diagnosis content, so how the condition is identified is not described here.

The packet contains no certified approved-treatments or foundational-therapies fields and no GeneReviews management content, so a treatment approach is not described here. Orphan drug records are present, each with status DESIGNATED except one with status WITHDRAWN. Designations cover agents sponsored for treatment or prevention of NEC, including Amnion-derived Cellular Cytokine Solution (Noveome Biotherapeutics) and melatonin (WORPHMED). An orphan designation is not marketing approval, and a withdrawn record is not a current option. One designated record in the list concerns necrotizing soft tissue infections and is not described as an NEC agent.

Prognosis is not certified in this packet, and no natural-history or survival information is provided beyond the definition's statement that the disease can lead to overwhelming infection and death.

The packet lists ten ClinicalTrials.gov records, with status and dates as recorded. NCT06315738, a Phase 1 study of ST266 in infants with NEC (sponsor Noveome Biotherapeutics), is listed as RECRUITING, with dates of 2024-08-19 to 2029-11-01. NCT05213806, withholding enteral feeds around blood transfusion (IWK Health Centre, phase NA), is RECRUITING. NCT07233382, a probiotics study for NEC prevention in preterm babies (Hayatabad Medical Complex), is ACTIVE_NOT_RECRUITING. Several other records are listed as NOT_YET_RECRUITING. The packet's literature digest classifies 225 publications, most commonly reviews or meta-analyses. No patient organizations are listed in the packet.